1. Scrip
  2. >>Therapy Areas

Private investment round-up: November 2008

 
• By Simon Varcoe

The amount raised by private companies in November was again bolstered by two large investment rounds that shored-up an otherwise disappointing month for the private sector, a Scrip analysis has found.

The amount raised by private companies in November was again bolstered by two large investment rounds that shored-up an otherwise disappointing month for the private sector, a Scrip analysis has found.

The total amount raised last month was $304.2 million, a 32% increase compared with October, though the figure benefited heavily...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapeutic Category

Novartis Secures Approval For First Malaria Therapy for Babies

 
• By Kevin Grogan

Coartem Baby to be rolled out in eight African countries in the autumn.

Could Apogee Rival Regeneron/Sanofi, Lilly After Phase II Eczema Data Win?

 
• By Manas Mishra

Apogee Therapeutics reports data from Phase II APEX trial of its long-acting antibody against atopic dermatitis, showing similar efficacy to Regeneron/Sanofi’s Dupixent and Eli Lilly’s Ebglyss.

Cogent Peaks With Bezaclastinib SUMMIT Results

 
• By Alaric DeArment

The biotech announced positive topline results from the Phase II SUMMIT study in non-advanced systemic mastocytosis, with data for advanced SM and GIST expected later this year.